Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, announced on Monday that it has entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase an equal number of shares. The combined transactions are expected to generate gross proceeds of approximately $2.9 million, before deducting placement agent fees and other offering expenses.
Under the terms of the agreements, the common shares are priced at $0.795 per share, and the warrants are priced at $0.005 per warrant. Each warrant carries an exercise price of $0.84 per share and will be exercisable immediately upon issuance, with a term of five and a half years from the date of issuance. The offerings are expected to close on or about August 14, 2026, subject to the satisfaction of customary closing conditions.
The company intends to use the net proceeds, together with its existing cash, cash equivalents, restricted cash, and investment-grade securities, for working capital and general corporate purposes. This capital infusion is expected to support Dyadic's ongoing development and commercialization efforts for its proprietary protein production platforms, which are designed to offer scalable, non-animal alternatives for producing high-value proteins.
Dyadic's technology, including its Dapibus™ and C1 expression systems, aims to enable rapid, cost-effective, and flexible manufacturing across diverse markets such as life sciences, food and nutrition, and bio-industrial applications. These platforms are positioned to address the growing global demand for sustainable and efficient protein production methods.
The offering is being led by Aegis Capital Corp. as the exclusive placement agent. This transaction highlights continued investor interest in biotechnology companies that offer innovative solutions for protein production, a sector that has seen increased attention due to supply chain challenges and sustainability concerns.
For more information about Dyadic International and its technologies, visit Dyadic's website. The full press release for this offering can be viewed at this link.
This capital raise comes at a time when the biotechnology industry is experiencing rapid advancements in alternative protein production. Dyadic's ability to secure funding from institutional investors underscores the potential of its platforms to meet the needs of customers seeking more efficient and sustainable production methods. The additional capital is expected to accelerate the company's product development timelines and expand its market reach.
Investors and industry observers will be watching how Dyadic deploys these funds to advance its pipeline and partnerships. The company's focus on non-animal protein production aligns with broader trends toward sustainability and ethical sourcing, which could provide long-term growth opportunities.
